Orano Med
Orano Med develops targeted cancer therapies using lead-212, focusing on Targeted Alpha Therapy (TAT) and has received FDA Breakthrough Therapy Designation for AlphaMedixTM.
Company Overview
Orano Med develops targeted therapies against cancer using lead-212, a rare alpha-emitting radioisotope. The company focuses on Targeted Alpha Therapy (TAT) by combining biological molecules with alpha-emitting radioisotopes. This approach is designed to target and destroy cancer cells with high precision.
Targeted Alpha Therapy
Orano Med specializes in Targeted Alpha Therapy (TAT), a technique that combines biological molecules with alpha-emitting radioisotopes to fight cancer. This method provides a targeted approach to treatment, aiming to minimize damage to healthy tissues while effectively targeting cancer cells. Orano Med has a pipeline of 212Pb-labeled compounds designed to target various cancer receptors and antigens.
FDA Breakthrough Therapy Designation
Orano Med received the Breakthrough Therapy Designation from the FDA for AlphaMedixTM, a therapy for treating gastroenteropancreatic neuroendocrine tumors. This designation highlights the potential of AlphaMedixTM as a promising treatment for patients with these types of tumors.
Production Capabilities
Orano Med operates an industrial platform capable of large-scale production of high-purity lead-212 at a reasonable cost. The company holds a proprietary source of raw material, thorium-232, which allows for independent production of 212Pb without the need for nuclear reactors or particle accelerators. Their patented chemical process ensures efficient production.
Global Expansion and ATLab Facilities
Orano Med plans to expand production facilities to meet commercial needs and global demand for Targeted Alpha Therapy drugs. The company has established ATLab facilities in the USA and France dedicated to the production and distribution of 212Pb-conjugated drugs. These facilities are crucial for ensuring a consistent supply of their targeted cancer therapies.